PURPOSE: Optimal margin size when resecting colorectal liver metastases (CRLM) remains unclear, particularly in the setting of perioperative chemotherapy. We evaluated the prognostic significance of margin size in patients who received neoadjuvant FOLFOX and/or FOLFIRI prior to resection of CRLM. METHODS: Clinicopathologic factors were collected for patients who underwent curative liver resections for CRLM between 4/2004-1/2016 and received neoadjuvant oxaliplatin and/or irinotecan and 5-FU (FOLFOX, FOLFIRI). Margins were categorized as < 1, ≥ 1-< 5, ≥ 5-< 10, or ≥ 10 mm and evaluated for association with overall survival (OS) and disease-free survival (DFS) by Cox multiple regression analysis. Margin status was classified as positive (< 1 mm) or negative (≥ 1 mm) and similarly evaluated. RESULTS: Of 227 patients, the median age was 58 years and most had synchronous (80%) lesions. The majority had colon cancers (75%). Margin sizes were 13% < 1 mm, 27% ≥ 1-< 5 mm, 23% ≥ 5-< 10 mm, 36% ≥ 10 mm. Most (63%) received chemotherapy post-liver resection. Five-year OS and DFS were 54% (95% CI 46-62%) and 22% (95% CI 16-28%), respectively. Positive margins significantly increased the risk of death without post-liver resection chemotherapy (HR = 3.32, p = 0.0077), but not with post-liver resection chemotherapy (HR = 1.00, p = 0.99). Negative margin sizes of ≥ 1-< 5, ≥ 5-< 10, and ≥ 10 mm were not significant predictors of OS (p > 0.05). CONCLUSION: Patients undergoing liver resection for CRLM should receive post-resection chemotherapy if negative margins (≥ 1 mm) cannot be achieved. For patients receiving FOLFOX and/or FOLFIRI chemotherapy, wider margins did not improve OS.
PURPOSE: Optimal margin size when resecting colorectal liver metastases (CRLM) remains unclear, particularly in the setting of perioperative chemotherapy. We evaluated the prognostic significance of margin size in patients who received neoadjuvant FOLFOX and/or FOLFIRI prior to resection of CRLM. METHODS: Clinicopathologic factors were collected for patients who underwent curative liver resections for CRLM between 4/2004-1/2016 and received neoadjuvant oxaliplatin and/or irinotecan and 5-FU (FOLFOX, FOLFIRI). Margins were categorized as < 1, ≥ 1-< 5, ≥ 5-< 10, or ≥ 10 mm and evaluated for association with overall survival (OS) and disease-free survival (DFS) by Cox multiple regression analysis. Margin status was classified as positive (< 1 mm) or negative (≥ 1 mm) and similarly evaluated. RESULTS: Of 227 patients, the median age was 58 years and most had synchronous (80%) lesions. The majority had colon cancers (75%). Margin sizes were 13% < 1 mm, 27% ≥ 1-< 5 mm, 23% ≥ 5-< 10 mm, 36% ≥ 10 mm. Most (63%) received chemotherapy post-liver resection. Five-year OS and DFS were 54% (95% CI 46-62%) and 22% (95% CI 16-28%), respectively. Positive margins significantly increased the risk of death without post-liver resection chemotherapy (HR = 3.32, p = 0.0077), but not with post-liver resection chemotherapy (HR = 1.00, p = 0.99). Negative margin sizes of ≥ 1-< 5, ≥ 5-< 10, and ≥ 10 mm were not significant predictors of OS (p > 0.05). CONCLUSION:Patients undergoing liver resection for CRLM should receive post-resection chemotherapy if negative margins (≥ 1 mm) cannot be achieved. For patients receiving FOLFOX and/or FOLFIRI chemotherapy, wider margins did not improve OS.
Authors: Chandrakanth Are; Mithat Gonen; Kathleen Zazzali; Ronald P Dematteo; William R Jarnagin; Yuman Fong; Leslie H Blumgart; Michael D'Angelica Journal: Ann Surg Date: 2007-08 Impact factor: 12.969
Authors: Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: B Cady; R L Jenkins; G D Steele; W D Lewis; M D Stone; W V McDermott; J M Jessup; A Bothe; P Lalor; E J Lovett; P Lavin; D C Linehan Journal: Ann Surg Date: 1998-04 Impact factor: 12.969
Authors: J Figueras; F Burdio; E Ramos; J Torras; L Llado; S Lopez-Ben; A Codina-Barreras; S Mojal Journal: Ann Oncol Date: 2007-04-13 Impact factor: 32.976
Authors: Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier Journal: Eur J Cancer Date: 2006-08-10 Impact factor: 9.162
Authors: Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; Felice Giuliante; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston Journal: Eur J Cancer Date: 2007-09-04 Impact factor: 9.162
Authors: Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica Journal: Ann Surg Date: 2015-09 Impact factor: 12.969
Authors: Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Vladimir A Valera; Pavel V Korita; Kouhei Akazawa; Yoichi Ajioka; Katsuyoshi Hatakeyama Journal: Ann Surg Oncol Date: 2008-07-02 Impact factor: 5.344
Authors: Renato Gomes Campanati; João Bernardo Sancio; Lucas Mauro de Andrade Sucena; Marcelo Dias Sanches; Vivian Resende Journal: Arq Bras Cir Dig Date: 2021-06-11
Authors: Jennie Engstrand; Cecilia Strömberg; Henrik Nilsson; Jacob Freedman; Eduard Jonas Journal: World J Surg Oncol Date: 2019-12-26 Impact factor: 2.754
Authors: Mariana I Chavez; Sepideh Gholami; Bradford J Kim; Georgios A Margonis; Cecilia G Ethun; Susan Tsai; Kathleen K Christians; Callisia Clarke; Harveshp Mogal; Shishir K Maithel; Timothy M Pawlik; Michael I D'Angelica; Thomas A Aloia; Daniel Eastwood; T Clark Gamblin Journal: Ann Surg Oncol Date: 2021-01-03 Impact factor: 5.344
Authors: Emilio De Raffele; Mariateresa Mirarchi; Dajana Cuicchi; Ferdinando Lecce; Claudio Ricci; Riccardo Casadei; Bruno Cola; Francesco Minni Journal: World J Gastrointest Oncol Date: 2018-10-15